Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Chudi O Ndubaku

3PUBLICATIONS
38CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Nov 06, 2025
Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Melissa R Junttila, Claire E Repellin, Sumeet Salaniwal

|Mar 22, 2020
NK cells mediate clearance of CD8<sup>+</sup> T cell-resistant tumors in response to STING agonists.

Christopher J Nicolai, Natalie Wolf, I-Chang Chang

|May 15, 2019
Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.

Marian C Bryan, Joy Drobnick, Alberto Gobbi

Pageof 1

Frequent Collaborators

1 joint publications

Marian C Bryan

1 joint publications

Jianwen Feng

1 joint publications

Edna F Choo

1 joint publications

Melissa R Junttila

1 joint publications

Claire E Repellin

1 joint publications

Sumeet Salaniwal

1 joint publications

Robert Warne

1 joint publications

Younho Lee

1 joint publications

Haelee Kim

1 joint publications

Kyung Ah Seo

Frequent Collaborators

1 joint publications

Marian C Bryan

1 joint publications

Jianwen Feng

1 joint publications

Edna F Choo

1 joint publications

Melissa R Junttila

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8<sup>+</sup> T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8<sup>+</sup> T Cells in Mice

Published on : Jun 12, 2021

7.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on : Oct 26, 2015

11.8K
See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8<sup>+</sup> T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8<sup>+</sup> T Cells in Mice

Published on : Jun 12, 2021

7.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on : Oct 26, 2015

11.8K
See more related videos